Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial

Georg Martin Haag, Christoph Springfeld, Barbara Grün, +12

European Journal of Cancer

MedicineImmunologyPathologyColorectal CancerImmune Checkpoint Inhibitor +5

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer

Alexander Stein, Donjetë Simnica, Christoph Schultheiß, +24

Journal for ImmunoTherapy of Cancer

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216).

Alexander Stein, Mascha Binder, Eray Goekkurt, +13

Journal of Clinical Oncology

Clinical ImmunologyImmunodeficienciesImmunologyImmune RegulationPathology +24

1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK

S-E. Al-Batran, Sylvie Lorenzen, Nils Homann, +17

Annals of Oncology

Surgical OncologyEsophagusEsophageal CancerGastrointestinal OncologyDante Trial +11

Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.

Georg Martin Haag, Niels Halama, Christoph Springfeld, +11

Journal of Clinical Oncology

Checkpoint InhibitionAdaptive Immune SystemImmunologyImmunoeditingPathology +16

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

Alexander Stein, Mascha Binder, Salah‐Eddin Al‐Batran, +12

Journal of Clinical Oncology

ImmunodeficienciesImmunologyImmunoeditingPathologyImmunotherapeutics +19

Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

Salah‐Eddin Al‐Batran, Claudia Pauligk, Ralf‐Dieter Hofheinz, +13

Journal of Clinical Oncology

Surgical OncologyGastroenterologyPathologySurgeryUpper Gastrointestinal Surgery +17

The synaptic vesicle protein <scp>SV</scp>31 assembles into a dimer and transports Zn²⁺

Lisa Waberer, Erik Henrich, Oliver Peetz, +4

Journal of Neurochemistry

Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.

Nils Homann, Sylvie Lorenzen, Michael Schenk, +17

Journal of Clinical Oncology

Surgical OncologyCancer ManagementGastroenterologySurgeryPharmacotherapy +18